BioSight
Therapeutics for Oncology and Hematological Disorders
Company Overview
Snapshot
Founded in November 1999 by Stela Gengrinovitch and Mark Gengrinovitch, BioSight operates with 1–10 employees. The company raised a total of $62.5M across 5 funding rounds from 9 investors. In October 2023, BioSight was acquired by Ayala Pharmaceuticals.
Business overview
BioSight is a clinical-stage biotechnology company focused on developing therapeutics for hematological malignancies and disorders. Its core product, BST-236 (INN aspacytarabine), is a proprietary anti-metabolite designed to deliver high-dose therapy with reduced systemic toxicity. The company serves the pharmaceutical and healthcare industries, specifically targeting oncology and hematology markets with its drug discovery and development efforts.
Strategic signal
In November 2022, BioSight initiated a Phase 1/2 clinical trial for aspacytarabine in combination with venetoclax for first-line AML induction therapy, followed by aspacytarabine consolidation. This development signals the company's continued commitment to advancing its lead product and exploring combination therapies to improve outcomes for acute myeloid leukemia patients, demonstrating ongoing clinical progress prior to its acquisition.
Log in to access full profile ›Company Intelligence Q&A
- What was BioSight's most recent corporate milestone?
- In October 2023, BioSight was acquired by Ayala Pharmaceuticals, leading to its current inactive status.
- When did BioSight last raise funding?
- In December 2020, BioSight closed a Series C financing round. Israel Biotech Fund led the round, with participation from Arkin Bio.
- What is BioSight's lead product?
- BioSight's lead product is BST-236 (INN aspacytarabine), an anti-metabolite currently being investigated as a single agent in a Phase 2b trial for first-line treatment of acute myeloid leukemia (AML).
- Has BioSight received any special designations for its drug candidates?
- In June 2019, BioSight received Orphan Drug Designation from the FDA for BST-236 for the treatment of acute myeloid leukemia. Additionally, in August 2020, the company was granted U.S. FDA Fast Track Designation for BST-236 for the same indication.
- Did BioSight engage in any clinical trial collaborations?
- In July 2020, BioSight announced a clinical trial collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies.